I'll be interested to hear what the PEB ASM has to say on Wednesday. As I see it, demand for and acceptance of cxbladder will continue to grow rapidly because of COVID.
Years ago the PEB royalty pipeline seemed to be the smallest and least likely to succeed (from Cellmid's perspective). The PEB long shot has now surpassed all of the early favourites. That's the way it goes sometimes.
I'll be interested to hear what the PEB ASM has to say on...
Add AN1 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| AN1 (ASX) Chart |
Day chart unavailable